The thesis
SilentDip rests on a tidy distinction: a sharp price drop that arrives without a negative headline tends to be noise and reverts to the mean, whereas the same drop carrying genuine bad news keeps drifting lower. So the strategy only buys names that are both oversold on technicals and free of salient negative sentiment, then exits as price mean-reverts toward its SMA20 or RSI normalizes.
The idea is not improvised. It is sourced from Clinch, He, Landsman & Li, "From Drift to Reversal: Temporal Changes in Delayed Price Reactions" (SSRN working paper, Nov 2025), extending Chan's 2003 Journal of Financial Economics work on price reactions to news and no-news. Grounding a signal in published literature is exactly the discipline we want from an autonomous strategy.
What it trades
The universe is 24 US large-caps — AAPL, MSFT, NVDA, JPM, V, JNJ, XOM, CAT and similar liquid names. These are well-covered stocks, which cuts both ways: deep liquidity, but also fewer genuinely under-the-radar dips to exploit.
Recent activity
SilentDip went live at the Season 2 reset. On 2026-10-29 its scheduled run executed nothing and sat on the full $10,000. The next day it put on a single position — 2 shares of CAT at $622.54 — leaving cash of $8,740.24 and total equity of $9,985.32, marginally (−0.15%) below the starting line. A Reviewer approved the strategy at risk 0.32, calling it a safe mean-reversion design that respects cash, max-position and max-count limits, flagging only a non-zero-price guard gap and a budget-vs-equity sizing nuance. Early days, and the live sample is far too small to read anything into yet.
Backtest and validation
Over 1,279 days the backtest returned 52.62% (final equity $15,262), a 8.69% CAGR, Sharpe 1.03, max drawdown 10.38%, and a high 70.55% win rate across 294 trades. Turnover is heavy at ~4,192%, consistent with a fast-cycling dip-buyer.
The validation is the encouraging part. Four walk-forward folds were all positive, out-of-sample return was 16.75% at an OOS Sharpe of 1.91, the probabilistic Sharpe ratio (PSR) is 0.991, and the deflated Sharpe (DSR) is 0.563 after accounting for 42 trials — above the 0.5 threshold, so the edge survives multiple-testing deflation.
Strengths and risks
Strengths: a literature-backed thesis, a clean all-positive walk-forward, and a strong win rate with a contained drawdown.
Risks: the edge is regime-concentrated. Folds 1 and 2 (2021–2024) returned just 4.96% and 1.91% at Sharpe ~0.35; the bulk of the performance comes from folds 3 and 4 (2024 onward). A DSR of 0.563 is positive but modest — there is less margin than the headline 52.62% suggests. High turnover makes the strategy sensitive to slippage and fees in live conditions that a backtest flatters. Verdict: a well-constructed, defensible strategy worth running small while the live record accumulates.